Lilly's experimental oral obesity drug, aleniglipron, helped patients lose up to 12.1% of their body weight in 36 weeks. Study completion rates were nearly identical to placebo, indicating high tolerability, according to Nature. Aleniglipron's ability to help patients lose up to 12.1% of their body weight in 36 weeks, with study completion rates nearly identical to placebo, positions it as a contender in the obesity treatment market.
Lilly is advancing this oral GLP-1, showing strong tolerability and significant weight loss. However, its more potent injectable drug, retatrutide, offering even greater weight loss, has surfaced a concerning neurological side effect.
The future of the obesity drug market will likely be defined by a strategic balance between maximal weight loss and an acceptable safety profile. Oral options could broaden market access despite slightly lower efficacy.
What We Know About Lilly's Next-Gen Obesity Drugs
Lilly's aleniglipron, an oral GLP-1, reduced body weight by up to 12.1% at 36 weeks (120 mg dose vs. 0.8% for placebo), according to Nature. Its study completion rates (73.3% to 78.1%) mirrored placebo (75.0%).
In contrast, Lilly's injectable retatrutide achieved 28.3% weight loss over 80 weeks in the Phase 3 TRIUMPH-1 study for obese patients without diabetes, and 26.6% placebo-adjusted weight loss at 68 weeks in TRIUMPH-4 for obese or overweight patients with knee osteoarthritis, per StatNews. However, TRIUMPH-4 also reported dysesthesia, a neurological signal, in over 20% of patients on the 20-mg retatrutide dose, with rates increasing at higher doses. The stark difference between retatrutide's 28.3% weight loss and the dysesthesia signal in over 20% of patients suggests a fundamental trade-off between maximal efficacy and patient safety.
For context, Novo's CagriSema showed a 23% average body weight loss at 84 weeks in the REDEFINE-4 study, as reported by Business Standard.
Weighing Efficacy and Safety
The efficacy gap is clear: retatrutide delivered 28.3% weight loss over 80 weeks, while aleniglipron achieved 12.1% over 36 weeks. This difference presents a critical trade-off for patients: maximal weight loss or superior tolerability and convenience. The dysesthesia signal in over 20% of retatrutide patients, with rates increasing at higher doses, makes this dilemma unavoidable. Companies focused only on peak weight loss, like retatrutide's 28.3%, risk ignoring the strategic advantage of better tolerability and ease of use.
Lilly's Strategic Approach
Aleniglipron's high study completion rates (73.3% to 78.1%) despite significant weight loss show that tolerability, not just efficacy, will drive market leadership and patient adherence. Aleniglipron's high study completion rates (73.3% to 78.1%) despite significant weight loss, showing that tolerability, not just efficacy, will drive market leadership and patient adherence, suggests Lilly recognizes the obesity market needs varied solutions.
Lilly is segmenting the market: a high-efficacy, potentially higher-risk injectable (retatrutide) and a highly tolerable, less potent oral option (aleniglipron). Lilly's strategy of segmenting the market with a high-efficacy, potentially higher-risk injectable (retatrutide) and a highly tolerable, less potent oral option (aleniglipron) challenges the idea that only injectables offer substantial weight loss, potentially expanding the patient pool. The dysesthesia signal in high-dose retatrutide patients forces Lilly and the market to weigh extreme efficacy against acceptable risk, likely slowing adoption of the most potent injectables.
The obesity drug market will likely see continued innovation balancing potent efficacy with tolerable safety profiles, potentially broadening access to treatment.
